October 13-15, 2020
100% Digital

8:00 am

Registration & Networking Coffee

8:50 am Chair’s Opening Remarks

• Anita Hill VP, Global Medical Affairs Lead for Haematology and Consultant for Clinical Development, Alexion

Understanding Complement Biology & Immunology in Disease

9:00 am Complement Factor H as a Novel Therapeutic Target in Cancer

• Edward Patz Chief Executive Officer, Grid Therapeutics

9:30 am Zilucoplan, a Self-Administered Subcutaneous Macrocyclic Peptide Inhibitor of Complement Component 5 (C5)

• Camil Sayegh Head of Complement Biology and Macrocycle Peptide Platform, UCB Ra Pharma

10:00 am Complement System Assessment in Erythropoietic Protoporphyria Patients

• Francesca Granata Research Biologist, Fondazione IRCCS Ca’Granda Ospedale Maggiore Policlinico di Milano

10:30 am

Speed Networking & Morning Refreshments

11:30 am Investigating Thrombomodulin’s Role in Complement Activation

• Julia Koeppe Assistant Professor of Chemistry, SUNY Oswego

Assay Validation

12:00 pm Landscape of Complement Diagnostics in the Era of Complement Drugs

• Elena Volokhina Assistant Professor, Radboud University

The Importance of Understanding Animal Models and Translation into the Human Analog

12:30 pm A Road Less Travelled: Finding a Path to a Human-Like Complement System in Animals

• Karoline Meagher Senior Staff Scientist, Regeneron

1:00 pm

Networking Lunch

2:00 pm The Anaphylatoxin Receptors as Targets in Autoantibody-Mediated Skin Diseases

• Joerg Koehl Professor and Director, Institute for Systemic Inflammation Research (ISEF), University of Luebeck

2:30 pm Panel Discussion on Translating Animal Models

• Karoline Meagher Senior Staff Scientist, Regeneron
• Joerg Koehl Professor and Director, Institute for Systemic Inflammation Research (ISEF), University of Luebeck
• Cynthia Lemere Associate Professor of Neurology, Harvard Medical School

Assessing Targeting Strategies

3:15 pm Inflammasome Activation, Complement System in Neuroimmunological Priming Following Environmental Stressors

• Giulio Pasinetti Professor of Neurology, Icahn School of Medicine at Mount Sinai

3:45 pm

Afternoon Refreshments

4:15 pm Details to be Confirmed

• Thomas Schall Chief Executive Officer, ChemoCentryx

4:45 pm Targeting the Complement System using siRNA Therapeutics

• Verena Aumiller Drug Discovery Project Leader, Silence Therapeutics

5:15 pm Targeting the Distal Terminal Complement Cascade for the t Treatment of Alzheimer’s Disease

• Christopher Campbell Chief Scientific Officer, Aurin Biotech

5:45 pm Chair’s Closing Remarks & End of Day One

• Michael Storek Head of Complement Cluster, Sanofi